"As the premier providers of medical eye surgery and LASIK, our team of board-certified ophthalmologists and eye doctors are committed to providing the highest quality eye care with services customized to your individual needs. Our staff of ophthalmologists provide treatment options for various types of conditions such as cataracts, glaucoma, macular degeneration, diabetic retinopathy, retinal tears or detachments, eye infections, and laser vision correction. We have been recognized as one of the industry’s innovators. Through our experience, commitment to technology, and role in researching new treatments and techniques we can provide patients the best possible eye care, both today and in the future."

During the past decade, Specialty Eye Institute conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 2 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 2 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Specialty Eye Institute" #1 collaborator was "Parexel" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Specialty Eye Institute" are "Geographic Atrophy" (2 trials), "Age-related Macular Degeneration" (1 trials), "Neovascular (Wet) Age-related Macular Degeneration (AMD)" (1 trials) and "Nonproliferative Diabetic Retinopathy" (1 trials). Many other conditions were trialed in "Specialty Eye Institute" in a lesser frequency.

Most popular intervention types in "Specialty Eye Institute" are "Drug" (4 trials), "Combination Product" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Lampalizumab" (2 trials), "ABP 938" (1 trials), "AKB-9778" (1 trials), "Aflibercept" (1 trials) and "Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Specialty Eye Institute" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Specialty Eye Institute". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Specialty Eye Institute, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Specialty Eye Institute, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".